GlassScriptPhysician profile
Ernest R Rector
NPI 1457432122
$1,830.67
in general payments reported to CMS, 2019-2025
11 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.16 · 2022: $238 · 2023: $402 · 2024: $489 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,202.73 | 2023-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $216.44 | 2022-2025 | |
| Pfizer INC. | $155.34 | 2019-2024 | |
| C. R. Bard, INC. & Subsidiaries | $47.96 | 2025 | Aptra |
| Urovant Sciences INC | $44.65 | 2022 | |
| Astellas Pharma US INC | $40.13 | 2019-2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $27.30 | 2024 | |
| Urogen Pharma, INC. | $26.65 | 2025 | |
| Myovant Sciences INC. | $26.51 | 2022 | |
| Abbvie INC. | $25.65 | 2022 | |
| Endo USA, INC. | $17.31 | 2024 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Rector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.